<DOC>
	<DOCNO>NCT01802476</DOCNO>
	<brief_summary>The purpose study determine approximately percentage orally administer dose PD-0332991 absorb gastrointestinal tract systemic circulation . This approximation make compare plasma pharmacokinetics 125 mg oral dose PD-0332991 plasma pharmacokinetics 50 mg intravenous dose PD-0332991 administer 4-hour infusion .</brief_summary>
	<brief_title>A Study Comparing Plasma Drug Exposure Oral Dose Palbociclib ( PD-0332991 ) Intravenous Dose Palbociclib ( PD-0332991 )</brief_title>
	<detailed_description />
	<mesh_term>Palbociclib</mesh_term>
	<criteria>1 . Healthy male female nonchildbearing potential age 18 55 year age . 2 . A body mass index ( BMI ) 17.5 30.5 kg/m2 , total body weight great 50kg ( 110 lb ) 1 . Any condition could possibly affect drug absorption . 2 . Pregnancy actively nursing female , female childbearing potential . 3 . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>PD-0332991</keyword>
	<keyword>Absolute Bioavailability Study</keyword>
</DOC>